Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD4-positive, alpha-beta T cell | 5 studies | 19% ± 4% | |
pericyte | 5 studies | 21% ± 6% | |
B cell | 4 studies | 17% ± 1% | |
T cell | 4 studies | 22% ± 5% | |
fibroblast | 4 studies | 20% ± 2% | |
CD8-positive, alpha-beta T cell | 4 studies | 18% ± 3% | |
natural killer cell | 4 studies | 20% ± 4% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 24% ± 2% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 20% ± 2% | |
conventional dendritic cell | 3 studies | 25% ± 7% | |
non-classical monocyte | 3 studies | 23% ± 7% | |
epithelial cell | 3 studies | 30% ± 9% | |
endothelial cell | 3 studies | 20% ± 4% | |
T follicular helper cell | 3 studies | 23% ± 2% | |
gamma-delta T cell | 3 studies | 21% ± 4% | |
regulatory T cell | 3 studies | 19% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 21% ± 5% | |
memory B cell | 3 studies | 20% ± 3% | |
glutamatergic neuron | 3 studies | 23% ± 3% | |
interneuron | 3 studies | 20% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 22% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 2094.88 | 459 / 459 | 100% | 76.94 | 1118 / 1118 |
esophagus | 100% | 1797.87 | 1445 / 1445 | 100% | 43.15 | 183 / 183 |
lung | 100% | 1829.93 | 578 / 578 | 100% | 45.68 | 1155 / 1155 |
ovary | 100% | 2371.22 | 180 / 180 | 100% | 46.81 | 430 / 430 |
prostate | 100% | 1239.44 | 245 / 245 | 100% | 43.52 | 501 / 502 |
liver | 100% | 1225.19 | 226 / 226 | 100% | 29.18 | 404 / 406 |
brain | 99% | 1174.61 | 2626 / 2642 | 100% | 52.47 | 705 / 705 |
thymus | 100% | 1443.81 | 652 / 653 | 100% | 51.93 | 602 / 605 |
uterus | 100% | 2030.50 | 170 / 170 | 99% | 38.81 | 456 / 459 |
stomach | 100% | 1393.20 | 359 / 359 | 99% | 32.70 | 284 / 286 |
bladder | 100% | 1581.71 | 21 / 21 | 99% | 38.10 | 500 / 504 |
intestine | 100% | 1824.94 | 966 / 966 | 99% | 33.54 | 522 / 527 |
pancreas | 100% | 858.38 | 328 / 328 | 99% | 34.05 | 176 / 178 |
kidney | 100% | 1015.70 | 89 / 89 | 98% | 35.77 | 887 / 901 |
skin | 100% | 2222.89 | 1809 / 1809 | 97% | 41.21 | 460 / 472 |
adrenal gland | 100% | 2481.20 | 258 / 258 | 97% | 39.50 | 222 / 230 |
adipose | 100% | 2357.64 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1913.23 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 28.03 | 29 / 29 |
muscle | 100% | 1432.90 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1504.30 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 34.49 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 44.33 | 1 / 1 |
heart | 98% | 1155.42 | 845 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 33.59 | 75 / 80 |
peripheral blood | 89% | 1187.51 | 825 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0070613 | Biological process | regulation of protein processing |
GO_0031648 | Biological process | protein destabilization |
GO_0060628 | Biological process | regulation of ER to Golgi vesicle-mediated transport |
GO_2000060 | Biological process | positive regulation of ubiquitin-dependent protein catabolic process |
GO_0036503 | Biological process | ERAD pathway |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0017148 | Biological process | negative regulation of translation |
GO_0012505 | Cellular component | endomembrane system |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0036513 | Cellular component | Derlin-1 retrotranslocation complex |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0019787 | Molecular function | ubiquitin-like protein transferase activity |
GO_0002020 | Molecular function | protease binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | RNF139 |
Protein name | E3 ubiquitin-protein ligase RNF139 (EC 2.3.2.27) (RING finger protein 139) (RING-type E3 ubiquitin transferase RNF139) (Translocation in renal carcinoma on chromosome 8 protein) Ring finger protein 139 |
Synonyms | TRC8 |
Description | FUNCTION: E3-ubiquitin ligase; acts as a negative regulator of cell proliferation through mechanisms involving G2/M arrest and cell death . Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER) . Affects SREBP processing by hindering the SREBP-SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression . Involved in the sterol-accelerated degradation of HMGCR . This is achieved through binding of RNF139 to INSIG1 and/or INSIG2 at the ER membrane . In addition, interaction of RNF139 with AUP1 facilitates interaction of RNF139 with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase AMFR, leading to ubiquitination of HMGCR . The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction . Required for INSIG1 ubiquitination . May be required for EIF3 complex ubiquitination . . |
Accessions | Q8WU17 E5RH85 ENST00000517684.2 ENST00000303545.4 ENST00000708475.1 |